4D Molecular Therapeutics, Inc.
FDMTNASDAQHealthcare● Active
$8.64
$-1.37(-13.69%)
Market Cap$451666835
P/E Ratio—
52W High$12.34
52W Low$3.68
4D Molecular Therapeutics, Inc. (FDMT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FDMT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.01
Est. -$0.97 · -4.1%
Revenue
$0.00B
Est. $0.00B · +17.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
FDMT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.97 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.97 | -$1.01 | -4.1% | $0.00B | $0.00B | +17.8% |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.53 | $0.43 | +181.1% | $0.09B | $0.03B | +215.2% |
| — Q4 FY2025 | Nov 10, 2025 | -$1.02 | -$1.01 | +1.0% | $0.00B | $0.03B | -99.7% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.88 | -$0.98 | -11.4% | $0.00B | $0.00B | +221.2% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.84 | -$0.86 | -2.4% | $0.00B | $0.00B | -97.4% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -$0.80 | -$0.90 | -12.5% | $0.00B | $0.00B | -100.0% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.67 | -$0.79 | -17.9% | $0.00B | $0.00B | -99.9% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.97
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.01
EPS Est.
-$0.97
EPS Surpr.
-4.1%
Revenue
$0.00B
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
$0.43
EPS Est.
-$0.53
EPS Surpr.
+181.1%
Revenue
$0.09B
Q4 FY2025
Nov 10, 2025
EPS Actual
-$1.01
EPS Est.
-$1.02
EPS Surpr.
+1.0%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.98
EPS Est.
-$0.88
EPS Surpr.
-11.4%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.86
EPS Est.
-$0.84
EPS Surpr.
-2.4%
Revenue
$0.00B
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
-$0.90
EPS Est.
-$0.80
EPS Surpr.
-12.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.79
EPS Est.
-$0.67
EPS Surpr.
-17.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.96 | $-0.96 | $-0.96 | 1 |
| Q3 FY2026 | $-0.97 | $-0.97 | $-0.96 | 5 |
| Q2 FY2026 | $-1.00 | $-0.97 | $-0.94 | 5 |
| Q1 FY2026 | $-1.15 | $-1.00 | $-0.86 | 6 |
| Q4 FY2025 | $-1.05 | $-0.53 | $0.40 | 7 |
| Q3 FY2025 | $-1.02 | $-0.98 | $-0.94 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2025 | $0.0B | $0.0B | $0.1B | 5 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -4.1% | $10.42 | $9.93 | -4.70% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +181.1% | $8.61 | $8.56 | -0.58% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +1.0% | $10.50 | $10.17 | -3.14% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -11.4% | $5.63 | $5.53 | -1.78% |
| ▼ Q2 FY2025 | May 8, 2025 | -2.4% | $3.12 | $3.24 | +3.85% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -12.5% | $4.48 | $4.53 | +1.12% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -17.9% | $7.87 | $7.71 | -2.03% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +12.5% | $14.71 | $14.73 | +0.14% |
Q2 FY2026-4.70%
Report Date
May 7, 2026
EPS Beat/Miss
-4.1%
Price Before
$10.42
Price After
$9.93
Q1 FY2026-0.58%
Report Date
Mar 18, 2026
EPS Beat/Miss
+181.1%
Price Before
$8.61
Price After
$8.56
Q4 FY2025-3.14%
Report Date
Nov 10, 2025
EPS Beat/Miss
+1.0%
Price Before
$10.50
Price After
$10.17
Q3 FY2025-1.78%
Report Date
Aug 11, 2025
EPS Beat/Miss
-11.4%
Price Before
$5.63
Price After
$5.53
Q2 FY2025+3.85%
Report Date
May 8, 2025
EPS Beat/Miss
-2.4%
Price Before
$3.12
Price After
$3.24
Q1 FY2025+1.12%
Report Date
Feb 28, 2025
EPS Beat/Miss
-12.5%
Price Before
$4.48
Price After
$4.53
Q4 FY2024-2.03%
Report Date
Nov 13, 2024
EPS Beat/Miss
-17.9%
Price Before
$7.87
Price After
$7.71
Q3 FY2024+0.14%
Report Date
Aug 8, 2024
EPS Beat/Miss
+12.5%
Price Before
$14.71
Price After
$14.73
Avg Beat Reaction-1.19%
Avg Miss Reaction-0.71%
Beat Rate3 / 8 quarters
Largest Move-4.70% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FDMT ends December
4D Molecular Therapeutics, Inc. (FDMT) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.01 — missing the analyst consensus of $-0.97 by -4.1%. The next FDMT earnings date is expected around September 1, 2026.
Each quarter, investors track FDMT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FDMT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FDMT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FDMT earnings · 5 questions4D Molecular Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. FDMT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FDMT historically reports after market close (AMC).
FDMT earnings datewhen is FDMT earningsFDMT next earnings datewhen does FDMT report earningsFDMT earnings calendar
▸ Source: FMP · 4D Molecular Therapeutics, Inc. SEC filings · US GAAP · 4D Molecular Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026